Free Trial
OTCMKTS:DSNKY

Daiichi Sankyo 4/25/2025 Earnings Report

Daiichi Sankyo logo
$24.49 +0.23 (+0.95%)
As of 08/28/2025 03:59 PM Eastern

Daiichi Sankyo EPS Results

Actual EPS
$0.30
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Daiichi Sankyo Revenue Results

Actual Revenue
$3.40 billion
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Daiichi Sankyo Announcement Details

Quarter
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Daiichi Sankyo's next earnings date is estimated for Thursday, October 30, 2025, based on past reporting schedules.

Conference Call Resources

Daiichi Sankyo Earnings Headlines

Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.tc pixel
See More Daiichi Sankyo Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Daiichi Sankyo? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Daiichi Sankyo and other key companies, straight to your email.

About Daiichi Sankyo

Daiichi Sankyo (OTCMKTS:DSNKY) Co., Ltd. is a global pharmaceutical company headquartered in Tokyo, Japan. Established in 2005 through the merger of Daiichi Pharmaceutical and Sankyo Company, the firm has grown into one of the leading Japanese research-driven healthcare organizations. It employs a vertically integrated business model, encompassing discovery research, clinical development, manufacturing and marketing of prescription medicines.

The company’s core focus areas include oncology, cardiovascular and metabolic diseases. Its oncology portfolio features trastuzumab deruxtecan (Enhertu), developed in collaboration with AstraZeneca, which has been approved for HER2-positive breast and gastric cancers. In cardiovascular care, Daiichi Sankyo markets products such as prasugrel (Effient) and olmesartan (Benicar) for the treatment and prevention of thrombotic and hypertensive disorders.

Daiichi Sankyo maintains a global footprint, with research and development centers in Japan, the United States and Europe. Its U.S. subsidiary, Daiichi Sankyo America, supports both clinical trials and commercial operations. The company also operates manufacturing facilities in Asia, North America and Europe, ensuring global supply of its key medicines and compliance with international regulatory standards.

Under the leadership of President and Chief Executive Officer Sunao Manabe, Daiichi Sankyo continues to invest in a robust pipeline, strategic alliances and next-generation technologies. The company’s long-term strategy emphasizes precision oncology, digital health initiatives and sustainable growth to address evolving patient needs and expand its presence in major pharmaceutical markets worldwide.

View Daiichi Sankyo Profile

More Earnings Resources from MarketBeat